MX366405B - Uso de peptidos glp-1 de accion prolongada. - Google Patents

Uso de peptidos glp-1 de accion prolongada.

Info

Publication number
MX366405B
MX366405B MX2014014946A MX2014014946A MX366405B MX 366405 B MX366405 B MX 366405B MX 2014014946 A MX2014014946 A MX 2014014946A MX 2014014946 A MX2014014946 A MX 2014014946A MX 366405 B MX366405 B MX 366405B
Authority
MX
Mexico
Prior art keywords
peptides
long
acting glp
glp
acting
Prior art date
Application number
MX2014014946A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014946A (es
Inventor
Bjørn Jensen Christine
Frederik Rasmussen Mads
Zdravkovic Milan
Kristensen Peter
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014014946A publication Critical patent/MX2014014946A/es
Publication of MX366405B publication Critical patent/MX366405B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2014014946A 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada. MX366405B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12174535 2012-07-01
US201261694837P 2012-08-30 2012-08-30
US201261708162P 2012-10-01 2012-10-01
EP12186781 2012-10-01
PCT/EP2013/063004 WO2014005858A1 (en) 2012-07-01 2013-06-21 Use of long-acting glp-1 peptides

Publications (2)

Publication Number Publication Date
MX2014014946A MX2014014946A (es) 2015-04-08
MX366405B true MX366405B (es) 2019-07-08

Family

ID=65858459

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014014946A MX366405B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2019008148A MX376058B (es) 2012-07-01 2013-06-21 Uso de peptidos glp-1 de accion prolongada.
MX2020010693A MX2020010693A (es) 2012-07-01 2014-12-05 Uso de peptidos glp-1 de accion prolongada.

Country Status (17)

Country Link
US (2) US9764003B2 (enExample)
EP (3) EP3689365B1 (enExample)
JP (1) JP6059802B2 (enExample)
AU (3) AU2013286177B2 (enExample)
BR (1) BR112014032938A2 (enExample)
CA (1) CA2877056A1 (enExample)
DK (1) DK2866825T3 (enExample)
ES (2) ES3041720T3 (enExample)
HR (2) HRP20251088T1 (enExample)
HU (2) HUE049152T2 (enExample)
MX (3) MX366405B (enExample)
PL (2) PL3689365T3 (enExample)
PT (1) PT2866825T (enExample)
RS (2) RS60432B1 (enExample)
RU (2) RU2018117557A (enExample)
SI (1) SI2866825T1 (enExample)
WO (1) WO2014005858A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
HUE049152T2 (hu) 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
KR102127624B1 (ko) * 2014-10-16 2020-06-29 얀마 파워 테크놀로지 가부시키가이샤 작업 차량
GB201621987D0 (en) * 2016-12-22 2017-02-08 Archer Virgil L See Archer Sheri A Arecor Ltd Novel composition
DE102017106216A1 (de) * 2017-03-22 2018-09-27 Amw Gmbh Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
CA3078652A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
GB201720187D0 (en) * 2017-12-04 2018-01-17 Imperial Innovations Ltd Novel Compounds
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TWI705820B (zh) 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
WO2020028907A1 (en) * 2018-08-03 2020-02-06 Brown University Compositions and methods for improving the bioavailability of glp1 and analogues thereof
WO2020072306A1 (en) * 2018-10-01 2020-04-09 Amgen Inc. Methods for reducing aggregation of bispecific antibodies
CA3131689A1 (en) * 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
WO2020180534A1 (en) 2019-03-01 2020-09-10 President And Fellows Of Harvard College Methods and compositions for protein delivery
CA3154744A1 (en) 2019-11-06 2021-05-14 Sarah FRIEDRICH Glp-1 receptor agonists in dementia
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
TW202228762A (zh) 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
US12605426B2 (en) 2020-02-14 2026-04-21 G2Gbio, Inc. Pharmaceutical comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof
IL294521A (en) * 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
CN112768087A (zh) * 2020-12-23 2021-05-07 吉林大学 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途
EP4359074A4 (en) * 2021-06-24 2025-06-04 Gila Therapeutics, Inc. METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
CA3237751A1 (en) 2021-11-10 2023-05-19 Tyler Brown Ionic liquid compositions
CN114874314B (zh) * 2021-12-28 2022-11-11 北京惠之衡生物科技有限公司 一种高表达glp-1类似物的重组工程菌及其构建方法
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2023225370A1 (en) * 2022-05-19 2023-11-23 Vault Bioventures, Inc. Obesity treatment and prevention methods
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
US20260007869A1 (en) 2023-06-23 2026-01-08 Vaxess Technologies, Inc. Microneedle array patches (maps), systems, and methods for manufacturing and using same
EP4750447A1 (en) 2023-07-24 2026-06-03 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for delivery of therapeutic peptides
WO2025165146A1 (ko) * 2024-01-29 2025-08-07 주식회사 티온랩테라퓨틱스 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
KR102930984B1 (ko) * 2024-01-29 2026-02-25 주식회사 티온랩테라퓨틱스 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법
WO2026046328A1 (en) * 2024-08-30 2026-03-05 Beijing Ql Biopharmaceutical Co., Ltd. Dosing regimen of glp-1 conjugates
CN118845644B (zh) * 2024-09-27 2025-01-17 杭州信海医药科技有限公司 一种司美格鲁肽注射液的制备方法
GB202418179D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
GB202418172D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
WO2026148333A2 (en) * 2025-01-06 2026-07-09 Sparrow Pharmaceuticals, Inc. Methods and compositions
WO2026161748A1 (en) 2025-01-23 2026-07-30 The Board Of Trustees Of The Leland Stanford Junior University Dynamic hydrogels for delivery of therapeutic peptides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
RU2413530C9 (ru) * 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
RU2409349C2 (ru) * 2006-04-14 2011-01-20 Маннкайнд Корпорейшн Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1)
EP2121897A4 (en) 2007-03-20 2010-03-31 Nippon Kayaku Kk METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
US20120329711A1 (en) 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
CN102203130B (zh) 2010-08-06 2014-06-25 贝达药业股份有限公司 Glp-1衍生物及其应用
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
US20140220134A1 (en) 2011-06-24 2014-08-07 Astrazeneca Pharamceuticals LP Method for treating diabetes with extended release formulation of glp-1 receptor agonists
HUE049152T2 (hu) 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása

Also Published As

Publication number Publication date
US10335462B2 (en) 2019-07-02
JP2015522573A (ja) 2015-08-06
ES3041720T3 (en) 2025-11-14
RU2657573C2 (ru) 2018-06-14
HRP20200889T1 (hr) 2020-09-04
EP3689365A1 (en) 2020-08-05
EP4406593A3 (en) 2024-10-23
HUE072859T2 (hu) 2025-12-28
US9764003B2 (en) 2017-09-19
PL2866825T3 (pl) 2021-02-22
PL3689365T3 (pl) 2025-11-12
MX2019008148A (es) 2019-09-05
RS60432B1 (sr) 2020-07-31
JP6059802B2 (ja) 2017-01-11
AU2013286177B2 (en) 2018-04-26
HRP20251088T1 (hr) 2025-11-07
MX2014014946A (es) 2015-04-08
RU2018117557A3 (enExample) 2021-08-20
AU2018202504B2 (en) 2020-05-07
PT2866825T (pt) 2020-07-15
US20180085435A1 (en) 2018-03-29
SI2866825T1 (sl) 2020-07-31
AU2020202573B2 (en) 2023-04-20
AU2020202573A1 (en) 2020-05-07
EP3689365B1 (en) 2025-08-06
EP4406593A2 (en) 2024-07-31
CA2877056A1 (en) 2014-01-09
MX376058B (es) 2025-03-07
RS67258B1 (sr) 2025-10-31
RU2018117557A (ru) 2019-03-22
RU2015101826A (ru) 2016-08-20
EP2866825B1 (en) 2020-04-08
BR112014032938A2 (pt) 2017-08-01
US20150190474A1 (en) 2015-07-09
DK2866825T3 (da) 2020-06-08
ES2796839T3 (es) 2020-11-30
HUE049152T2 (hu) 2020-09-28
AU2018202504A1 (en) 2018-05-10
MX2020010693A (es) 2020-11-06
WO2014005858A1 (en) 2014-01-09
AU2013286177A1 (en) 2015-01-15
EP2866825A1 (en) 2015-05-06
EP3689365C0 (en) 2025-08-06

Similar Documents

Publication Publication Date Title
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
CL2021000008A1 (es) Uso de un heparinoide para el tratamiento del cáncer (divisional de la solicitud n° 201403017)
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
BR112013029256A8 (pt) combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2
UA118558C2 (uk) Пептидна сполука
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
DK2728002T3 (da) Heterodimeriseret polypeptid
CL2015001699A1 (es) Compuestos derivados de nucleosidos, nucleotidos y analogos de los mismos; composicion farmaceutica; y su uso para preparar un medicamento util en el tratamiento de la hepatitis c.
EA201690780A1 (ru) Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
MX371187B (es) Péptidos terapéuticos.
CL2013002001A1 (es) Uso de un agonista del receptor tipo toll para el tratamiento del cancer.
DK2940135T3 (da) Heterodimeriseret polypeptid
CL2015001731A1 (es) Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras.
UY34859A (es) Análogos peptídicos de la exendina 4.
PE20151239A1 (es) Derivados de exendina-4 funcionalizada
PE20151178A1 (es) Analogos de glucagon
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
PL2707015T5 (pl) Liksysenatyd jako terapia uzupełniająca do insuliny bazalnej w cukrzycy typu 2
CL2014001705A1 (es) Compuestos derivados de aza adamantano, inhibidores de 11beta-hsd-1; composicion farmaceutica; metodo para prevencion o tratamiento; y uso para prevenir o tratar el sindrome metabolico, diabetes tipo 2 como consecuencia de obesidad, resisitencia a insulina, dislipidemia, neuropatia, isquemia e infarto, entre otras enfermedades.
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
BR112015006692A2 (pt) formulação de nanodispersão, método para administrar uma formulação de nanodispersão líquida de taxina livre de etanol em um indivíduo, e, kit.
EA201490041A1 (ru) Пластырь, содержащий диклофенак и тиоколхикозид

Legal Events

Date Code Title Description
FG Grant or registration